



**Rule Category:**  
Medical

**Ref: No:**  
2013-MN-0005

**Version Control:**  
Version No. 3.0

**Effective Date:**  
30-08-2018

**Revision Date:**  
August 2019



# Benign Prostatic Hyperplasia

## Adjudication Guideline

### Table of content

<b>Abstract</b> Page 1	<b>Scope</b> Page 2	<b>Adjudication Policy</b> Page 2	<b>Denial codes</b> Page 3	<b>Appendices</b> Page 3
---------------------------	------------------------	--------------------------------------	-------------------------------	-----------------------------

### Abstract

#### For Members

Benign prostatic hyperplasia/hypertrophy (BPH) is a common condition in men associated with an increase in the size of the prostate gland, potentially slowing or blocking the urinary stream. In some men, it may lead to lower urinary tract symptoms (LUTS) such as the need to urinate frequently, dribbling or leaking of urine, a need to strain during urination, a sensation of incomplete bladder emptying etc.

#### For Medical Professionals

Benign prostatic hyperplasia (also known as hypertrophy), is a common benign condition in men associated with an increase in the size of the prostate that may or may not lead to lower urinary tract symptoms (LUTS). LUTS can be categorized into voiding, storage or post-micturition symptoms and can be graded into mild, moderate or severe, based on the IPSS (International Prostate Symptom Score) as follows:

- Mild: score 0-7
- Moderate: score 8-19
- Severe: score 20-35

**Approved by:**  
Daman

**Responsible:**  
Medical Standards & Research

**Related Adjudication Guidelines:**  
None

#### Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.

## Scope

This guideline specifies all the coverage details for the management of Benign Prostatic Hyperplasia (BPH) for all the health insurance plans administered by Daman.

## Adjudication Policy

### Eligibility / Coverage Criteria

Daman covers management of BPH (including both investigations and treatments) for all health insurance plans administered by Daman, as per policy terms and conditions.

#### 1. Diagnostic modalities/investigations:

##### a) Routine Tests:

- Severity and bother (i.e. AUA-SI)
- Frequency or volume chart
- Urinalysis
- DRE (Digital Rectal Examination)
- PSA (Prostate Specific Antigen) - will not be covered if done on the same day as DRE

##### b) Specialist Tests /Optional Tests:

In general, optional tests are done during a detailed evaluation and ordered by a urologist

- Flow Rate recording
- Residual urine
- Pressure flow studies
- Prostate imaging by trans abdominal or trans rectal ultrasound
- Upper urinary tract imaging with ultrasonography, computer tomography, intravenous urography
- Cystoscopy

#### 2. Conservative management

It is considered a part of E/M. Coverage of containment products is subject to policy terms and conditions.

#### 3. Medical management

Daman covers pharmacological management of BPH based on medical necessity and in accordance with international best practice and evidence-based medicine.

#### 4. Surgical Management

Daman will only cover surgical treatments for BPH if the following criteria are met and documented:

##### a) Lower urinary tract symptoms (LUTS) refractory to other therapies

##### b) If ANY of the following conditions appear:

- Renal insufficiency
- Hydronephrosis
- Gross hematuria
- Recurrent or persistent urinary tract infections
- Large bladder diverticula associated with progressive bladder dysfunction
- Bladder stones
- Acute urinary retention refractory to treatment

## Requirements for Coverage

ICD and CPT codes must be coded to the highest level of specificity.

## Non-Coverage

1. Daman does not cover any treatment of BPH for the Visitors Plan.
2. Coverage of the following treatments for BPH will be subject to policy terms and conditions:
  - a) Homeopathy/ Alternate medicines/ Phytotherapy
  - b) Acupuncture

Experimental/unproven treatments or treatments that are not considered medically necessary are NOT covered for any health insurance plan administered by Daman.

## Payment and Coding Rules

Please apply HAAD payment rules and regulations and relevant coding manuals for ICD, CPT, etc.

## Denial codes

Code description
Service is not clinically indicated based on good clinical practice
Service is not clinically indicated based on good clinical practice, without additional supporting diagnoses/activities
Prior approval is required and was not obtained
Claim information is inconsistent with pre-certified/authorized services
Diagnosis is inconsistent with the patient's gender
Diagnosis/es is(are) not covered
Service(s) is (are) not covered
Payment is included in the allowance for another service

## Appendices

### A. References

1. American Urological Association Education and Research, Inc. (2018). Guideline on the Management of Benign Prostatic Hyperplasia (BPH). American Urological Association Education and Research, Inc. ®. 1 (1), 1-34.
2. BMJ. (2011). Benign Prostatic Hyperplasia. Available: <http://bestpractice.bmj.com/best-practice/monograph/208.html>. Last accessed 9th Aug 2012.
3. Jean Gray, BSC. MD (2007). Therapeutic Choices. 5th ed. Canada: Canadian Pharmacists Association. 783
4. John Hopkins Medicine Health Library. (). Cystometry. Available at: [http://www.hopkinsmedicine.org/healthlibrary/test\\_procedures/urology/cystometry\\_92,P07718/](http://www.hopkinsmedicine.org/healthlibrary/test_procedures/urology/cystometry_92,P07718/). Last accessed 9th Aug 2012.

5. National Clinical Guideline Centre. (2010).The management of lower urinary tract symptoms in men. National Clinical Guideline Centre. 1 (1), p1-355.
6. Raymond Rackley, MD. (). Urodynamic Studies for Urinary Incontinence. Available at: <http://emedicine.medscape.com/article/1988665-overview#aw2aab6c11>. Last accessed 9th Aug 2012.
7. WebMD. (31-01-2011). Prostate-Specific Antigen (PSA). Available at: <http://men.webmd.com/prostate-specific-antigen-psa#hw5525>. Last accessed 9-08-2012.
8. Smith CP. (2009). Botulinum toxin in the treatment of OAB, BPH, and IC. US National Library of Medicine National Institutes of Health. 1 (1)
9. Medpedia. (). Clinical: Benign Prostatic Hyperplasia (BPH). Available at: [http://wiki.medpedia.com/Clinical:Benign\\_Prostatic\\_Hyperplasia\\_\(BPH\)](http://wiki.medpedia.com/Clinical:Benign_Prostatic_Hyperplasia_(BPH)). Last accessed 23rd Sept 2012
10. S Ventura. (2011). Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). British Journal of Pharmacology. 1 (1), 891–907.
11. FDA. (2011). Benign Prostatic Hyperplasia. Available at: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm274642.htm>. Last accessed 23rd Sept 2012.
12. NKUDIC. (June 2006). State Enlargement: Benign Prostatic Hyperplasia. Available at: <http://kidney.niddk.nih.gov/kudiseases/pubs/prostateenlargement/>. Last accessed 23rd Sept 2012. (HIFU)
13. Karaman M Ihsan; Kaya Cevdet; Ozturk Metin; Gurdal Mesut; Kirecci Sinan; Pirincci Necip . (2005). Comparison of Transurethral Vaporization using Plasma Kinetic Energy and Transurethral Resection of Prostate: 1-year follow-up. Journal of Endourology/ Endourological Society. 19 (1), 734-7. (PKV)
14. Fung Berry Tat-Chow; Li Shu-Keung; Yu Chris Fong; Lau Ban-Eng; Hou Simon See-Ming . (2005). Prospective randomized controlled trial comparing plasma kinetic vaporesction and conventional transurethral resection of the prostate. . Asian Journal of Surgery. 28 (1), 24-8.(PKV)
15. J A Vale, P D Miller, and R S Kirby. (1993). Balloon dilatation of the prostate--should it have a place in the urologist's armamentarium? JRSM-Journal of the Royal Society of Medicine. 86 (2), 83–86.
16. American Urological Association Education and Research, Inc. (2003). AUA Guideline on the Management of Benign Prostatic. AUA. 1 (1), 1-54.

## B. Revision History

Date	Change
01-07-13	V1.1: New template
15-07-14	V 2.0 Disclaimer updated as per system requirements
01-08-18	V3.0 Content update